Efficiency of Using Veloz in Treatment of Patients with Gastroesophageal Reflux Disease

Yu.M. Stepanov, I.Ya. Budzak

Abstract


The article presents the review of clinical trials on the evaluation of efficiency of rabeprazole in patients with gastroesophageal reflux disease. The results of own investigation concerning the efficiency of generic rabeprazole — Veloz — in patients with this pathology were also shown. The results of clinical evaluation and pH-monitoring showed the efficiency of Veloz.

Keywords


gastroesophageal reflux disease; treatment; rabeprazole

References


Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group / C. Birbara, J. Breiter, C. Perdomo, W. Hahne // Eur. J. Gastroenterol. Hepatol. — 2000. — Vol. 12. — P. 889-97.

Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease / P. Bytzer, A. Blum, D. De Herdt [et al.] // Aliment. Pharmacol. Ther. — 2004. — Vol. 20. — P. 181-8.

Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment / P. Bytzer, A. Morocutti, P. Kennerly [et al.] // Scand. J. Gastroenterol. — 2006. — Vol. 41. — P. 1132-40.

Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States / A. Caos, J. Breiter, C. Perdomo, J. Barth // Aliment. Pharmacol. Ther. — 2005. — Vol. 22. — P. 193-202.

Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care — prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg / A. Eggleston, P.H. Katelaris, S. Nandurkar [et al.] // Aliment. Pharmacol. Ther. — 2009 — Vol. 29. — P. 967-78.

Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease — a double-blind, placebo-controlled, randomized study / R. Fass, B. Delemos, L. Nazareno [et al.] // Aliment. Pharmacol. Ther. — 2010. — P. 865-888.

Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia / K.M. Fock, E.K. Teo, T.L. Ang [et al.] // World J. Gastroenterol. — 2005. — Vol. 11. — P. 3091-8.

Sleep dysfunction in Japanese patients with gastroesophageal reflux disease: prevalence, risk factors, and efficacy of rabeprazole / Y. Fujiwara, Y. Kohata, M. Kaji [et al.] // Digestion. — 2010. — Vol. 81. — P. 135-41.

A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease / G. Holtmann, P. Bytzer, M. Metz [et al.] // Aliment. Pharmacol. Ther. — 2002. — Vol. 15. — P. 479-85.

Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors — focus on rabeprazole / J. Horn // Aliment. Pharmacol. Ther. — 2004. — Vol. 20 (Suppl. 6.). — P. 11-19.

Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease / P.J. Kahrilas, P. Miner, J. Johanson [et al.] // Dig. Dis. Sci. — 2005. — Vol. 50. — P. 2009-18.

The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease / X.H. Liu, M.Y. Ke, Z.Q. Song [et al.] // Zhonghua Nei Ke Za Zhi. — 2005. — Vol. 44. — P. 818-21.

Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study / Miner P. Jr, Katz P.O., Chen Y., Sostek M. // Am. J. Gastroenterol. — 2003. — Vol. 98. — P. 2616-20.

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial / Miner P. Jr, Orr W., Filippone J. [et al.] // Am. J. Gastroenterol. — 2002. — Vol. 97. — P. 1332-9.

Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-hour intragastric acidity and oesophageal acid exposure: a randomised, study in gastroesophageal reflux disease (GERD) patients with a history of nocturnal heartburn / P. Miner, B. Delemos, J. Xiang [et al.] // Aliment. Pharmacol. Ther. — 2010. —

Р. 570-575.

Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg / D.G. Morgan, M.F. O’Mahony, W.F. O’Mahony [et al.] // Can. J. Gastroenterol. — 2007. — Vol. 21. — P. 820-6.

Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors / S.V. Morozov, O.M. Tsodikova, V.A. Isakov [et al.] // Eksp. Kl. Gastroenterol. — 2003. — 6. — 58-63

Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole / Y. Muro, K. Sugiura, Y. Nitta [et al.] // Clin. Exp. Rheumatol. — 2009. — Vol. 27. — P. 15-21.

Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole / F. Pace, V. Annese, A. Prada [et al.] // Dig. Liver Dis. — 2005. — Vol. 37. — P. 741-50.

A review of rabeprazole in the treatment of acid-related diseases / F. Pace, S. Pallotta, S. Casalini, G.B. Porro // Ther. Clin. Risk Manag. — 2007. — Vol. 3. — P. 363-79.

Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis / M. Robinson, S. Fitzgerald, R. Hegedus [et al.] // Aliment. Pharmacol. Ther. — 2002. — Vol. 16. — P. 445-54.

Röhss K. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms / K. Röhss, T. Lind, C. Wilder-Smith // Eur. J. Clin. Pharmacol. — 2004. — Vol. 60. — P. 531-9.

A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years / B. Thjodleifsson, G. Rindi, R. Fiocca [et al.] // Aliment. Pharmacol. Ther. — 2003. — Vol. 17. — P. 343-51.

Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn / S. Warrington, K. Baisley, D. Lee [et al.] // Aliment. Pharmacol. Ther. — 2007. — Vol. 25. — P. 511-7.

Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? / N.J. Wit, W.A. Boer, H. Geldof [et al.] // Aliment. Pharmacol. Ther. — 2004. — Vol. 20. — P. 451-8.

Long-term impact on quality of life in patients with gastroesophageal reflux disease after 52-week rabeprazole treatment / X.L. Yang, X.H. Liu, M.Y. Ke [et al.] // Zhonghua Yi Xue Za Zhi. — 2009 — Vol. 89. — P. 2404-7.




DOI: https://doi.org/10.22141/2308-2097.3.49.2013.86283

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru